EDIT Editas Medicine Inc

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:

• Morgan Stanley 22nd Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 4Time: 4:05 p.m. ETLocation: New York, NY

• 2024 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Thursday, September 5Time: 4:30 p.m. ETLocation: Boston, MA

• 2024 Cantor Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, September 17Time: 1:20 p.m. ETLocation: New York, NY

• Chardan 8th Annual Genetic Medicines ConferenceFormat: Fireside ChatDate: Tuesday, October 1Time: 4:00 p.m. ETLocation: New York, NY

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas MedicineAs a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com